Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
With the UK seemingly heading towards an exit from the European Union in just two and a half years’ time, restrictions on the free movement of people, products and finance will impact the life science sector as much as, if not more than, many others.
Denmark, France, Ireland, Italy, Spain and Sweden have all have expressed a keen interest in hosting the European Medicines Agency once the UK leaves the EU. Bids are expected to be made sometime early next year, probably once the UK government triggers Article 50. There is at present no formal process for allocating an agency to a particular EU country, as this tends to be done via a process of political wrangling, so each prospective candidate will need to garner as much support for their bid as possible from the other member states.
Latest From Brexit
The first life sciences-focused specialized investment fund, BioPharma Credit, has completed an IPO in London, lifting the spirits of the investment community pondering the long-term consequences of the country withdrawing from the EU.
Companies could lose hundreds of millions of dollars thanks to the impact of Brexit on international reference pricing. Brexit has other market access implications too, for example on the ebb and flow of parallel trade.
Pharma leaders in the UK and Europe have had a stormy start to the week, as the UK government revealed its aim to leave the single market and the OECD issued a loud call for drug makers to restrain their prices.
As we enter a new year, Scrip takes a look at the five biggest themes that got the most hits from our readers over the last 12 months.
Few would argue that 2016 threw a number of curveballs into the global arena. With the New Year upon us, Scrip took a deep breath and asked a number of internal and external contributors across the pharma and biotech spectrum for their expectations for 2017.
Delivering clinical advances in areas including immuno-oncology and Alzheimer's disease data while navigating the stormy seas of global politics could represent an opportunity for pharma to influence change. An uptick in sector M&A could also ensue if Trump offers US corporations a tax holiday.
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.